Everest Refocuses After Trodelvy Twist

 
• By Dexter Jie Yan

A shift in investor sentiment in 2021 hit Everest hard when it was expanding the commercial team for cancer drug Trodelvy. Entering 2022, the sustained downturn in the capital market environment eventually changed the way the Chinese biotech considers launching drugs in the market.

Trodelvy sale
Everest has used more than 95% of cash it allocated to Trodelvy following 2020 IPO • Source: Shutterstock

More from China

More from Focus On Asia